Cargando…

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2

In the ongoing coronavirus disease 2019 (COVID-19) pandemic, there remain unanswered questions regarding the nature and significance of the humoral immune response toward other coronavirus infections. Here, we investigate the cross-reactivity of antibodies raised against the first severe acute respi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Timothy A., Weinstein, Jules B., Farley, Scotland, Leier, Hans C., Messer, William B., Tafesse, Fikadu G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835103/
https://www.ncbi.nlm.nih.gov/pubmed/33545052
http://dx.doi.org/10.1016/j.celrep.2021.108737
_version_ 1783642441589456896
author Bates, Timothy A.
Weinstein, Jules B.
Farley, Scotland
Leier, Hans C.
Messer, William B.
Tafesse, Fikadu G.
author_facet Bates, Timothy A.
Weinstein, Jules B.
Farley, Scotland
Leier, Hans C.
Messer, William B.
Tafesse, Fikadu G.
author_sort Bates, Timothy A.
collection PubMed
description In the ongoing coronavirus disease 2019 (COVID-19) pandemic, there remain unanswered questions regarding the nature and significance of the humoral immune response toward other coronavirus infections. Here, we investigate the cross-reactivity of antibodies raised against the first severe acute respiratory syndrome coronavirus (SARS-CoV) for their reactivity toward SARS-CoV-2. We extensively characterize a selection of 10 antibodies covering all of the SARS-CoV structural proteins: spike, membrane, nucleocapsid, and envelope. Although nearly all of the examined SARS-CoV antibodies display some level of reactivity to SARS-CoV-2, we find only partial cross-neutralization for the spike antibodies. The implications of our work are two-fold. First, we establish a set of antibodies with known reactivity to both SARS-CoV and SARS-CoV-2, which will allow further study of both viruses. Second, we provide empirical evidence of the high propensity for antibody cross-reactivity between distinct strains of human coronaviruses, which is critical information for designing diagnostic and vaccine strategies for COVID-19.
format Online
Article
Text
id pubmed-7835103
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s).
record_format MEDLINE/PubMed
spelling pubmed-78351032021-01-26 Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 Bates, Timothy A. Weinstein, Jules B. Farley, Scotland Leier, Hans C. Messer, William B. Tafesse, Fikadu G. Cell Rep Article In the ongoing coronavirus disease 2019 (COVID-19) pandemic, there remain unanswered questions regarding the nature and significance of the humoral immune response toward other coronavirus infections. Here, we investigate the cross-reactivity of antibodies raised against the first severe acute respiratory syndrome coronavirus (SARS-CoV) for their reactivity toward SARS-CoV-2. We extensively characterize a selection of 10 antibodies covering all of the SARS-CoV structural proteins: spike, membrane, nucleocapsid, and envelope. Although nearly all of the examined SARS-CoV antibodies display some level of reactivity to SARS-CoV-2, we find only partial cross-neutralization for the spike antibodies. The implications of our work are two-fold. First, we establish a set of antibodies with known reactivity to both SARS-CoV and SARS-CoV-2, which will allow further study of both viruses. Second, we provide empirical evidence of the high propensity for antibody cross-reactivity between distinct strains of human coronaviruses, which is critical information for designing diagnostic and vaccine strategies for COVID-19. The Author(s). 2021-02-16 2021-01-26 /pmc/articles/PMC7835103/ /pubmed/33545052 http://dx.doi.org/10.1016/j.celrep.2021.108737 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bates, Timothy A.
Weinstein, Jules B.
Farley, Scotland
Leier, Hans C.
Messer, William B.
Tafesse, Fikadu G.
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title_full Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title_fullStr Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title_full_unstemmed Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title_short Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
title_sort cross-reactivity of sars-cov structural protein antibodies against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835103/
https://www.ncbi.nlm.nih.gov/pubmed/33545052
http://dx.doi.org/10.1016/j.celrep.2021.108737
work_keys_str_mv AT batestimothya crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2
AT weinsteinjulesb crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2
AT farleyscotland crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2
AT leierhansc crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2
AT messerwilliamb crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2
AT tafessefikadug crossreactivityofsarscovstructuralproteinantibodiesagainstsarscov2